Scolaris Content Display Scolaris Content Display

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 1 Severe exacerbation requiring OCS.
Figuras y tablas -
Analysis 1.1

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 1 Severe exacerbation requiring OCS.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 2 Withdrawal due to worsening asthma.
Figuras y tablas -
Analysis 1.2

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 2 Withdrawal due to worsening asthma.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 3 FEV1 (L) change from baseline.
Figuras y tablas -
Analysis 1.3

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 3 FEV1 (L) change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 4 FEV1 (percent predicted).
Figuras y tablas -
Analysis 1.4

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 4 FEV1 (percent predicted).

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 5 Morning PEF (L/min) change from baseline.
Figuras y tablas -
Analysis 1.5

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 5 Morning PEF (L/min) change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 6 Evening PEF (L/min) change from baseline.
Figuras y tablas -
Analysis 1.6

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 6 Evening PEF (L/min) change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 7 Rescue medications (puffs/day) change from baseline.
Figuras y tablas -
Analysis 1.7

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 7 Rescue medications (puffs/day) change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 8 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 1.8

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 8 Percent Rescue Free Days change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 9 Percent Symptom Free Days.
Figuras y tablas -
Analysis 1.9

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 9 Percent Symptom Free Days.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 10 Symptom Score change from baseline.
Figuras y tablas -
Analysis 1.10

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 10 Symptom Score change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 11 Night Waking change from baseline.
Figuras y tablas -
Analysis 1.11

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 11 Night Waking change from baseline.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 12 Adverse Events.
Figuras y tablas -
Analysis 1.12

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 12 Adverse Events.

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 13 Overall Withdrawals.
Figuras y tablas -
Analysis 1.13

Comparison 1 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS, Outcome 13 Overall Withdrawals.

Comparison 2 LABA + reduced/tapering dose ICS vs reduced/tapering dose ICS, Outcome 1 FEV1 (L) change from baseline.
Figuras y tablas -
Analysis 2.1

Comparison 2 LABA + reduced/tapering dose ICS vs reduced/tapering dose ICS, Outcome 1 FEV1 (L) change from baseline.

Comparison 2 LABA + reduced/tapering dose ICS vs reduced/tapering dose ICS, Outcome 2 Morning PEF (L/min) change from baseline.
Figuras y tablas -
Analysis 2.2

Comparison 2 LABA + reduced/tapering dose ICS vs reduced/tapering dose ICS, Outcome 2 Morning PEF (L/min) change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 1 Withdrawal due to worsening asthma.
Figuras y tablas -
Analysis 3.1

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 1 Withdrawal due to worsening asthma.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 2 FEV1 (L) change from baseline.
Figuras y tablas -
Analysis 3.2

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 2 FEV1 (L) change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 3 Morning PEF (L/min) change from baseline.
Figuras y tablas -
Analysis 3.3

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 3 Morning PEF (L/min) change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 4 Evening PEF (L/min) change from baseline.
Figuras y tablas -
Analysis 3.4

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 4 Evening PEF (L/min) change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 5 Rescue medications change from baseline.
Figuras y tablas -
Analysis 3.5

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 5 Rescue medications change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 6 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 3.6

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 6 Percent Rescue Free Days change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 7 Percent symptom free days change from baseline.
Figuras y tablas -
Analysis 3.7

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 7 Percent symptom free days change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 8 Symptom Score change from baseline.
Figuras y tablas -
Analysis 3.8

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 8 Symptom Score change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 9 Night Waking change from baseline.
Figuras y tablas -
Analysis 3.9

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 9 Night Waking change from baseline.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 10 Adverse Events.
Figuras y tablas -
Analysis 3.10

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 10 Adverse Events.

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 11 Overall Withdrawals.
Figuras y tablas -
Analysis 3.11

Comparison 3 LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS), Outcome 11 Overall Withdrawals.

Comparison 4 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control), Outcome 1 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 4.1

Comparison 4 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control), Outcome 1 Percent Rescue Free Days change from baseline.

Comparison 4 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control), Outcome 2 Percent Symptom Free Days change from baseline.
Figuras y tablas -
Analysis 4.2

Comparison 4 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control), Outcome 2 Percent Symptom Free Days change from baseline.

Comparison 4 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control), Outcome 3 Symptom Score change from baseline.
Figuras y tablas -
Analysis 4.3

Comparison 4 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control), Outcome 3 Symptom Score change from baseline.

Comparison 5 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device), Outcome 1 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 5.1

Comparison 5 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device), Outcome 1 Percent Rescue Free Days change from baseline.

Comparison 5 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device), Outcome 2 Percent Symptom Free Days change from baseline.
Figuras y tablas -
Analysis 5.2

Comparison 5 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device), Outcome 2 Percent Symptom Free Days change from baseline.

Comparison 5 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device), Outcome 3 Symptom Score change from baseline.
Figuras y tablas -
Analysis 5.3

Comparison 5 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device), Outcome 3 Symptom Score change from baseline.

Comparison 6 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality), Outcome 1 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 6.1

Comparison 6 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality), Outcome 1 Percent Rescue Free Days change from baseline.

Comparison 6 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality), Outcome 2 Percent Symptom Free Days change from baseline.
Figuras y tablas -
Analysis 6.2

Comparison 6 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality), Outcome 2 Percent Symptom Free Days change from baseline.

Comparison 6 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality), Outcome 3 Symptom Score change from baseline.
Figuras y tablas -
Analysis 6.3

Comparison 6 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality), Outcome 3 Symptom Score change from baseline.

Comparison 7 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA), Outcome 1 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 7.1

Comparison 7 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA), Outcome 1 Percent Rescue Free Days change from baseline.

Comparison 7 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA), Outcome 2 Percent Symptom Free Days change from baseline.
Figuras y tablas -
Analysis 7.2

Comparison 7 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA), Outcome 2 Percent Symptom Free Days change from baseline.

Comparison 7 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA), Outcome 3 Symptom Score change from baseline.
Figuras y tablas -
Analysis 7.3

Comparison 7 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA), Outcome 3 Symptom Score change from baseline.

Comparison 8 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration), Outcome 1 Percent Rescue Free Days change from baseline.
Figuras y tablas -
Analysis 8.1

Comparison 8 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration), Outcome 1 Percent Rescue Free Days change from baseline.

Comparison 8 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration), Outcome 2 Percent Symptom Free Days change from baseline.
Figuras y tablas -
Analysis 8.2

Comparison 8 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration), Outcome 2 Percent Symptom Free Days change from baseline.

Comparison 8 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration), Outcome 3 Symptom Score change from baseline.
Figuras y tablas -
Analysis 8.3

Comparison 8 LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration), Outcome 3 Symptom Score change from baseline.

Comparison 1. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Severe exacerbation requiring OCS Show forest plot

2

484

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.76, 1.32]

2 Withdrawal due to worsening asthma Show forest plot

3

1270

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.50, 1.35]

3 FEV1 (L) change from baseline Show forest plot

4

1388

Mean Difference (IV, Fixed, 95% CI)

0.10 [0.07, 0.12]

4 FEV1 (percent predicted) Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

4.1 Change from baseline

1

454

Mean Difference (IV, Fixed, 95% CI)

2.70 [0.06, 5.34]

4.2 End of Study

2

455

Mean Difference (IV, Fixed, 95% CI)

3.62 [1.65, 5.59]

5 Morning PEF (L/min) change from baseline Show forest plot

4

1388

Mean Difference (IV, Fixed, 95% CI)

16.68 [9.13, 24.24]

6 Evening PEF (L/min) change from baseline Show forest plot

3

1100

Mean Difference (IV, Fixed, 95% CI)

12.56 [4.90, 20.22]

7 Rescue medications (puffs/day) change from baseline Show forest plot

4

1388

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.25, 0.03]

8 Percent Rescue Free Days change from baseline Show forest plot

3

1100

Mean Difference (IV, Random, 95% CI)

9.21 [1.36, 17.05]

9 Percent Symptom Free Days Show forest plot

5

Mean Difference (IV, Random, 95% CI)

Subtotals only

9.1 Change from baseline

4

1388

Mean Difference (IV, Random, 95% CI)

3.71 [‐1.14, 8.57]

9.2 End of Study

1

60

Mean Difference (IV, Random, 95% CI)

10.90 [‐7.40, 29.20]

10 Symptom Score change from baseline Show forest plot

3

1100

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.40, 0.09]

11 Night Waking change from baseline Show forest plot

2

1012

Mean Difference (IV, Fixed, 95% CI)

0.02 [‐0.09, 0.12]

12 Adverse Events Show forest plot

3

1436

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.79, 1.07]

13 Overall Withdrawals Show forest plot

3

1436

Risk Ratio (M‐H, Fixed, 95% CI)

0.97 [0.74, 1.28]

Figuras y tablas -
Comparison 1. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS
Comparison 2. LABA + reduced/tapering dose ICS vs reduced/tapering dose ICS

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (L) change from baseline Show forest plot

2

127

Mean Difference (IV, Fixed, 95% CI)

0.21 [0.00, 0.41]

2 Morning PEF (L/min) change from baseline Show forest plot

2

127

Mean Difference (IV, Fixed, 95% CI)

7.80 [‐14.24, 29.85]

Figuras y tablas -
Comparison 2. LABA + reduced/tapering dose ICS vs reduced/tapering dose ICS
Comparison 3. LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Withdrawal due to worsening asthma Show forest plot

1

558

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.36, 1.34]

1.1 Fixed dose ICS control group

1

558

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.36, 1.34]

1.2 Reduced/tapering dose ICS control group

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 FEV1 (L) change from baseline Show forest plot

4

1134

Mean Difference (IV, Fixed, 95% CI)

0.10 [0.07, 0.12]

2.1 Fixed dose ICS control group

3

1100

Mean Difference (IV, Fixed, 95% CI)

0.10 [0.07, 0.12]

2.2 Reduced/tapering dose ICS control group

1

34

Mean Difference (IV, Fixed, 95% CI)

0.2 [‐0.33, 0.73]

3 Morning PEF (L/min) change from baseline Show forest plot

4

1134

Mean Difference (IV, Fixed, 95% CI)

15.59 [7.89, 23.29]

3.1 Fixed dose ICS control group

3

1100

Mean Difference (IV, Fixed, 95% CI)

15.79 [7.70, 23.87]

3.2 Reduced/tapering dose ICS control group

1

34

Mean Difference (IV, Fixed, 95% CI)

13.7 [‐11.43, 38.83]

4 Evening PEF (L/min) change from baseline Show forest plot

4

1134

Mean Difference (IV, Fixed, 95% CI)

12.45 [5.05, 19.84]

4.1 Fixed dose ICS control group

3

1100

Mean Difference (IV, Fixed, 95% CI)

12.56 [4.90, 20.22]

4.2 Reduced/tapering dose ICS control group

1

34

Mean Difference (IV, Fixed, 95% CI)

10.90 [‐17.28, 39.08]

5 Rescue medications change from baseline Show forest plot

4

1134

Std. Mean Difference (IV, Random, 95% CI)

‐0.15 [‐0.30, 0.01]

5.1 Fixed dose ICS control group

3

1100

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.24, ‐0.00]

5.2 Reduced/tapering dose ICS control group

1

34

Std. Mean Difference (IV, Random, 95% CI)

‐0.79 [‐1.50, ‐0.09]

6 Percent Rescue Free Days change from baseline Show forest plot

3

1100

Mean Difference (IV, Random, 95% CI)

9.21 [1.36, 17.05]

6.1 Fixed dose ICS control group

3

1100

Mean Difference (IV, Random, 95% CI)

9.21 [1.36, 17.05]

6.2 Reduced/tapering dose ICS control group

0

0

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

7 Percent symptom free days change from baseline Show forest plot

3

1100

Mean Difference (IV, Fixed, 95% CI)

6.00 [1.86, 10.15]

7.1 Fixed dose ICS control group

3

1100

Mean Difference (IV, Fixed, 95% CI)

6.00 [1.86, 10.15]

7.2 Reduced/tapering dose ICS control group

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Symptom Score change from baseline Show forest plot

3

1100

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.40, 0.09]

8.1 Fixed dose ICS control group

3

1100

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.40, 0.09]

8.2 Reduced/tapering dose ICS control group

0

0

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

9 Night Waking change from baseline Show forest plot

2

1012

Mean Difference (IV, Fixed, 95% CI)

0.02 [‐0.09, 0.12]

9.1 Fixed dose ICS control group

2

1012

Mean Difference (IV, Fixed, 95% CI)

0.02 [‐0.09, 0.12]

9.2 Reduced/tapering dose ICS control group

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Adverse Events Show forest plot

3

1046

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.80, 1.07]

10.1 Fixed dose ICS control group

2

1012

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.79, 1.08]

10.2 Reduced/tapering dose ICS control group

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.63, 1.36]

11 Overall Withdrawals Show forest plot

2

1012

Risk Ratio (M‐H, Fixed, 95% CI)

1.03 [0.65, 1.61]

11.1 Fixed dose ICS control group

2

1012

Risk Ratio (M‐H, Fixed, 95% CI)

1.03 [0.65, 1.61]

11.2 Reduced/tapering dose ICS control group

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 3. LABA + reduced/tapering dose ICS vs ICS alone (uncontrolled on < mod dose ICS)
Comparison 4. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Percent Rescue Free Days change from baseline Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 Controlled

2

646

Mean Difference (IV, Random, 95% CI)

5.34 [0.16, 10.52]

1.2 Uncontrolled

1

454

Mean Difference (IV, Random, 95% CI)

16.1 [8.33, 23.87]

1.3 Unknown

0

0

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Percent Symptom Free Days change from baseline Show forest plot

4

Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Controlled

2

646

Mean Difference (IV, Random, 95% CI)

5.76 [0.81, 10.70]

2.2 Uncontrolled

1

454

Mean Difference (IV, Random, 95% CI)

6.60 [‐1.03, 14.23]

2.3 Unknown

1

288

Mean Difference (IV, Random, 95% CI)

‐4.30 [‐13.17, 4.57]

3 Symptom Score change from baseline Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

3.1 Controlled

2

646

Std. Mean Difference (IV, Random, 95% CI)

‐0.31 [‐0.76, 0.14]

3.2 Uncontrolled

1

454

Std. Mean Difference (IV, Random, 95% CI)

0.03 [‐0.16, 0.21]

3.3 Unknown

0

0

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 4. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (asthma control)
Comparison 5. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Percent Rescue Free Days change from baseline Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 pMDI

1

454

Mean Difference (IV, Random, 95% CI)

16.1 [8.33, 23.87]

1.2 DPI

2

646

Mean Difference (IV, Random, 95% CI)

5.34 [0.16, 10.52]

2 Percent Symptom Free Days change from baseline Show forest plot

4

Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 pMDI

1

454

Mean Difference (IV, Random, 95% CI)

6.60 [‐1.03, 14.23]

2.2 DPI

3

934

Mean Difference (IV, Random, 95% CI)

2.29 [‐4.68, 9.25]

3 Symptom Score change from baseline Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

3.1 pMDI

1

454

Std. Mean Difference (IV, Random, 95% CI)

0.03 [‐0.16, 0.21]

3.2 DPI

2

646

Std. Mean Difference (IV, Random, 95% CI)

‐0.31 [‐0.76, 0.14]

Figuras y tablas -
Comparison 5. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (device)
Comparison 6. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Percent Rescue Free Days change from baseline Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 Jadad >=3

2

1012

Mean Difference (IV, Random, 95% CI)

10.39 [‐0.07, 20.85]

1.2 Jadad < 3

1

88

Mean Difference (IV, Random, 95% CI)

4.90 [‐9.61, 19.41]

2 Percent Symptom Free Days change from baseline Show forest plot

4

Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Jadad >=3

3

1300

Mean Difference (IV, Random, 95% CI)

3.44 [‐2.63, 9.52]

2.2 Jadad < 3

1

88

Mean Difference (IV, Random, 95% CI)

4.00 [‐10.14, 18.14]

3 Symptom Score change from baseline Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

3.1 Jadad >=3

2

1012

Std. Mean Difference (IV, Random, 95% CI)

‐0.05 [‐0.19, 0.09]

3.2 Jadad < 3

1

88

Std. Mean Difference (IV, Random, 95% CI)

‐0.59 [‐1.02, ‐0.16]

Figuras y tablas -
Comparison 6. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (quality)
Comparison 7. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Percent Rescue Free Days change from baseline Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 FP/Salm

3

1100

Mean Difference (IV, Random, 95% CI)

9.21 [1.36, 17.05]

1.2 BUD/Form

0

0

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Percent Symptom Free Days change from baseline Show forest plot

4

Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 FP/Salm

4

1388

Mean Difference (IV, Random, 95% CI)

3.71 [‐1.14, 8.57]

2.2 BUD/Form

0

0

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 Symptom Score change from baseline Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

3.1 FP/Salm

3

1100

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.40, 0.09]

3.2 BUD/Form

0

0

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 7. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (ICS/LABA)
Comparison 8. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Percent Rescue Free Days change from baseline Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 <= 24 weeks

3

1100

Mean Difference (IV, Random, 95% CI)

9.21 [1.36, 17.05]

1.2 > 24 weeks

0

0

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Percent Symptom Free Days change from baseline Show forest plot

4

Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 <= 24 weeks

4

1388

Mean Difference (IV, Random, 95% CI)

3.71 [‐1.14, 8.57]

2.2 > 24 weeks

0

0

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 Symptom Score change from baseline Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

3.1 <= 24 weeks

3

1100

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.40, 0.09]

3.2 > 24 weeks

0

0

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 8. LABA + reduced/tapering dose ICS vs fixed mod/high dose ICS (duration)